Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Q-Cells · 1 trial · 1 indication
Safety will be measured by the number of therapy related adverse events.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Unilateral lumbar surgical transplantation of Q-Cells dose level 1 |
| Cohort 2 | EXPERIMENTAL | Unilateral cervical surgical transplantation of Q-Cells dose level 1 |
| Cohort 3 | EXPERIMENTAL | Unilateral cervical surgical transplantation of Q-Cells dose level 2 |
| Cohort 4 | EXPERIMENTAL | Unilateral cervical surgical transplantation of Q-Cells dose level 3 |
| Cohort 5 | EXPERIMENTAL | Unilateral cervical surgical transplantation of Q-Cells dose level 4 |
| Cohort 6 | EXPERIMENTAL | Unilateral cervical surgical transplantation of Q-Cells dose level 5 |
| Name | Type | Description |
|---|---|---|
| Q-Cells | BIOLOGICAL | cellular therapeutic comprised of human cells of the glial lineage |
Inclusion Criteria: 1. Subject has the ability to understand the purpose and risks of the study and provide a signed and dated informed consent and authorization to collect and use protected health information (PHI) in accordance with national and local subject privacy regulations. 2. Subject lives...
Q-Cells is an investigational cell therapy being studied for the treatment of Amyotrophic Lateral Sclerosis (ALS). It is currently in Phase 1 clinical development, with an active trial investigating the safety of transplanting human glial restricted progenitor cells into subjects with ALS.
Q-Cells is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational therapy for Amyotrophic Lateral Sclerosis.
Q-Cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety in patients with Amyotrophic Lateral Sclerosis.
Q-Cells is being studied in a Phase 1 clinical trial registered as NCT02478450. This trial is investigating the safety of transplanting human glial restricted progenitor cells into subjects with Amyotrophic Lateral Sclerosis. The study is not yet recruiting and aims to enroll 30 participants.
Q-Cells is a brand name for human glial restricted progenitor cells (hGRPs). The investigational therapy consists of these cells, which are being studied for their potential role in treating Amyotrophic Lateral Sclerosis through transplantation into affected individuals.